{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:09:39Z","timestamp":1785247779723,"version":"3.55.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>No universal gold standard chemotherapy exists for the treatment of older (\u226560 years) patients with classical Hodgkin lymphoma (cHL). To evaluate the current curative treatment strategies used in the Nordic countries, we collected data from patients diagnosed in Sweden, Denmark and Norway during the years 2000 to 2021. We included 1569 patients: 704 (45%) Swedish, 671 (43%) Danish, and 194 (12%) Norwegian. Of these, 671 (43%) received doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), 123 (8%) received doxorubicin, vinblastine, and dacarbazine (AVD), 465 (31%) received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), and 212 (13%) received other chemotherapy (single agent or combination). Eighty-two (5%) patients lacked information on first-line regimen. In multivariable analyses of overall survival (OS), treatment with AVD was associated with improved survival compared to ABVD, whereas there was a trend toward inferior survival among patients receiving CHOP or other regimens. For progression-free survival (PFS), multivariable analysis likewise demonstrated significantly improved outcome with AVD relative to ABVD, whereas outcomes for the CHOP group were comparable to ABVD. Outcome for patients receiving other regimens tended to be poorer. Collectively, outcome for AVD with respect to both OS and PFS was at least equal to ABVD and often superior to CHOP. By omitting bleomycin, treatment-related toxicity is known to be reduced in AVD compared to ABVD. Based on our findings, AVD is a preferable chemotherapy option in older patients with cHL and should rightly be considered as backbone in treatment with novel drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018954","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T20:33:30Z","timestamp":1775075610000},"page":"4889-4897","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["AVD is an effective chemotherapy backbone in first-line treatment of older patients with classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9222-9619","authenticated-orcid":false,"given":"Ninja","family":"\u00d6vergaard","sequence":"first","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"},{"name":"2Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"Lia","sequence":"additional","affiliation":[{"name":"3Medical Department, B\u00e6rum Hospital, Vestre Viken Hospital Trust, Gjettum, Norway"},{"name":"4Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"5Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremia","family":"Collin","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"},{"name":"6Department of Oncology, Akademiska University Hospital, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Asdahl","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Wikman","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-3041","authenticated-orcid":false,"given":"Ingrid","family":"Glimelius","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar","family":"Lagerl\u00f6f","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"},{"name":"8Department of Hematology, University Hospital of Link\u00f6ping, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sofie","family":"Johansson","sequence":"additional","affiliation":[{"name":"9Department of Diagnostics and Intervention, Ume\u00e5 University, Ume\u00e5, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6614-5737","authenticated-orcid":false,"given":"Lotta","family":"Hansson","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Linderoth","sequence":"additional","affiliation":[{"name":"11Department of Oncology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1263-7538","authenticated-orcid":false,"given":"Christina","family":"Goldkuhl","sequence":"additional","affiliation":[{"name":"12Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Jerlstr\u00f6m","sequence":"additional","affiliation":[{"name":"13Department of Oncology, \u00d6rebro University Hospital, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Foss\u00e5","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-1969","authenticated-orcid":false,"given":"Peter","family":"Kamper","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6662-4865","authenticated-orcid":false,"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[{"name":"1Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"5","key":"2026072809364138300_bib1","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10428194.2018.1522435","article-title":"Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis","volume":"60","author":"Major","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2026072809364138300_bib2","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/bloodadvances.2021004645","article-title":"Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma","volume":"5","author":"Orellana-Noia","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2026072809364138300_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann Hematol"},{"issue":"22","key":"2026072809364138300_bib4","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026072809364138300_bib5","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/1097-0142(19930301)71:5<1857::AID-CNCR2820710524>3.0.CO;2-B","article-title":"Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B","volume":"71","author":"Mir","year":"1993","journal-title":"Cancer"},{"issue":"8","key":"2026072809364138300_bib6","first-page":"982","article-title":"Hodgkin's lymphoma in the elderly: a different disease in patients over 60","volume":"21","author":"Klimm","year":"2007","journal-title":"Oncology (Williston Park)"},{"issue":"18","key":"2026072809364138300_bib7","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"Boll","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2026072809364138300_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br J Haematol"},{"issue":"9976","key":"2026072809364138300_bib9","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"2026072809364138300_bib10","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"issue":"15","key":"2026072809364138300_bib11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin's lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"10450","key":"2026072809364138300_bib12","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"2026072809364138300_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2340\/1651-226X.2024.40431","article-title":"The National Swedish Lymphoma Register - a systematic validation of data quality","volume":"63","author":"Ekstr\u00f6m Smedby","year":"2024","journal-title":"Acta Oncol"},{"issue":"6","key":"2026072809364138300_bib14","doi-asserted-by":"crossref","first-page":"e0157999","DOI":"10.1371\/journal.pone.0157999","article-title":"The Danish National Lymphoma Registry: coverage and data quality","volume":"11","author":"Arboe","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"2026072809364138300_bib15","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.ejca.2008.10.037","article-title":"Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness","volume":"45","author":"Larsen","year":"2009","journal-title":"Eur J Cancer"},{"issue":"5","key":"2026072809364138300_bib16","first-page":"1403","article-title":"Overall survival and causes of death in elderly patients with Hodgkin lymphoma: a Norwegian population-based case-control study","volume":"109","author":"Lia","year":"2024","journal-title":"Haematologica"},{"issue":"3","key":"2026072809364138300_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jha2.202","article-title":"Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged &gt;60 years","volume":"2","author":"Wahlin","year":"2021","journal-title":"EJHaem"},{"issue":"1","key":"2026072809364138300_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/ejh.13090","article-title":"Greater attention should be paid to developing therapies for elderly patients with Hodgkin lymphoma-A population-based study from Sweden","volume":"101","author":"Bjorkholm","year":"2018","journal-title":"Eur J Haematol"},{"issue":"11","key":"2026072809364138300_bib19","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"2026072809364138300_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0165-1781(92)90005-N","article-title":"Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale","volume":"41","author":"Miller","year":"1992","journal-title":"Psychiatry Res"},{"issue":"5","key":"2026072809364138300_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative Illness Rating Scale","volume":"16","author":"Linn","year":"1968","journal-title":"J Am Geriatr Soc"},{"key":"2026072809364138300_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/CLEP.S282475","article-title":"Adaptation of the Charlson Comorbidity Index for register-based research in Sweden","volume":"13","author":"Ludvigsson","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"7","key":"2026072809364138300_bib23","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"2026072809364138300_bib24","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0959-8049(99)00319-6","article-title":"Measuring comorbidity in older cancer patients","volume":"36","author":"Extermann","year":"2000","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026072809364138300_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2026072809364138300_bib26","doi-asserted-by":"crossref","first-page":"e70190","DOI":"10.1002\/hem3.70190","article-title":"Brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone for advanced-stage Hodgkin lymphoma in older patients","volume":"9","author":"Brockelmann","year":"2025","journal-title":"Hemasphere"},{"issue":"2","key":"2026072809364138300_bib27","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.19475","article-title":"Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a matched background population: a Danish national cohort study","volume":"205","author":"Vandtved","year":"2024","journal-title":"Br J Haematol"},{"issue":"1","key":"2026072809364138300_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026072809364138300_bib29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2023-185818","article-title":"Bleomycin affects lung function for at least 5 years after treatment for Hodgkin lymphoma - data from the international, randomised phase 3 Rathl trial","volume":"142","author":"Phillips","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2026072809364138300_bib30","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1080\/10428190601126610","article-title":"Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma","volume":"48","author":"Kolstad","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026072809364138300_bib31","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1200\/JCO-24-01278","article-title":"Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma","volume":"43","author":"Torka","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026072809364138300_bib32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2023021564","article-title":"The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients","volume":"143","author":"Ghesquieres","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026072809364138300_bib33","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1182\/blood.2022019536","article-title":"Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy","volume":"143","author":"Friedberg","year":"2024","journal-title":"Blood"},{"issue":"30","key":"2026072809364138300_bib34","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026072809364138300_bib35","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026072809364138300_bib36","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.17384","article-title":"The use of frailty assessments in treating older adults with aggressive lymphomas","volume":"194","author":"Cordoba","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"2026072809364138300_bib37","first-page":"2356","article-title":"A simplified frailty score predicts outcome in curatively treated older patients with classical Hodgkin lymphoma","volume":"110","author":"Lia","year":"2025","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4889\/2533294\/blooda_adv-2025-018954-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/4889\/2533294\/blooda_adv-2025-018954-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:36:51Z","timestamp":1785245811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/4889\/567535\/AVD-is-an-effective-chemotherapy-backbone-in-first"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018954","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,15]]}}}